X

Trial Profile

A Phase II Study of Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; Dexamethasone
Indications Mantle-cell lymphoma
Focus Therapeutic Use

Most Recent Events

20 May 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
29 Apr 2019 Planned End Date changed from 1 Jan 2023 to 1 Jul 2021.
29 Apr 2019 Planned primary completion date changed from 1 Jan 2023 to 1 Jul 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com